Joanne Soo

TL;DR: Pretreatment ctDNA levels and molecular responses are independently prognostic of outcomes in aggressive lymphomas, and these risk factors could potentially guide future personalized risk-directed approaches.

TL;DR: The Continuous Individualized Risk Index is described, a method to dynamically determine outcome probabilities for individual patients utilizing risk predictors acquired over time that envision that dynamic risk assessment will facilitate personalized medicine and enable innovative therapeutic paradigms.

TL;DR: In this paper, a method called PhasED-seq (Phased Variational Enrichment and Detection SeqSeq) was proposed, which uses multiple somatic mutations in individual DNA fragments to improve the sensitivity of ctDNA detection.

TL;DR: In this paper , a method called EPIC-seq was proposed to infer gene expression profiles from cell-free DNA (cfDNA) using targeted sequencing of promoters of genes of interest.

TL;DR: In this paper , the authors used epigenetic expression inference from cell-free DNA-sequencing (EPIC-seq) to detect lung carcinoma and diffuse large B cell lymphoma.